Weiss Asset Management LP - 19 Sep 2022 Form 3 Insider Report for Theravance Biopharma, Inc. (TBPH)

Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
3
Accepted by SEC
28 Sep 2022, 09:33:40 UTC
Prior SEC filing
19 Aug 2021
Next SEC filing
18 Feb 2026
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
Georgiy Nikitin, Chief Compliance Officer, Weiss Asset Management LP and WAM GP LLC

Key filing fact

Weiss Asset Management LP filed Form 3 for Theravance Biopharma, Inc. (TBPH) on 28 Sep 2022.

Key facts

  • This page summarizes Weiss Asset Management LP's Form 3 filing for Theravance Biopharma, Inc. (TBPH).
  • 0 reported transactions and 0 derivative rows are listed below.
  • Accepted by SEC: 28 Sep 2022, 09:33.

Change

  • Previous filing in this sequence was filed on 19 Aug 2021.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Official SEC source

Ownership activity is grounded in SEC Form 3 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

TBPH holding

Ordinary shares

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
7,457,060
Date
19 Sep 2022
Ownership
See Footnote 1
Footnotes
F1
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Shares reported herein represent shares beneficially owned by two private investment funds for which Weiss Asset Management LP serves as investment manager. WAM GP LLC is the general partner of Weiss Asset Management LP and Andrew Weiss is the Manager of WAM GP LLC. All of Weiss Asset Management LP, WAM GP LLC, and Andrew Weiss disclaim beneficial ownership of the shares reported herein except to the extent of their pecuniary interest therein.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .